Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: A systematic review and economic evaluation

BMC Endocrine Disorders

Volumn 9, Issue , 2009, Pages 20-

  Moore, David J ^a   Adi, Yaser ^b   Connock, Martin J ^a   Bayliss, Sue ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE DERIVATIVE; PEGVISOMANT; PLACEBO; SOMATOMEDIN C;

ACCIDENTAL INJURY; ACROMEGALY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DATA EXTRACTION; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FLATULENCE; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPOPHYSIS TUMOR; INFECTION; INJECTION SITE REACTION; INSOMNIA; LIFE EXPECTANCY; NAUSEA; PAIN; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; SIDE EFFECT; SINUSITIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 70449713587     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-9-20     Document Type: Article

References (42)

1. Melmed S, Melmed S. Medical progress: Acromegaly. [Review] [102 refs]. New England Journal of Medicine 2006, 355:2558-2573. 10.1056/NEJMra062453, 17167139.
2. Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis 2008, 3:17. 10.1186/1750-1172-3-17, 2459162, 18578866.
3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25:102-152. 10.1210/er.2002-0022, 14769829.
4. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999, 2:29-41. 10.1023/A:1009965803750, 11081170.
5. Pfizer Limited Somavert: Summary of Product Characteristics. 2004, Accessed August 2007., http://emc.medicines.org.uk/medicine/14353/SPC/SOMAVERT+10mg%2c+15mg+%26 +20mg+powder+and+solvent+for+solution+for+injection/
6. NHS Centre for Reviews and Dissemination University of York Undertaking systematic reviews of research on effectiveness: CRDs guidance for those carrying out or commisioning reviews. 4. 2001, 2.
7. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. The New England journal of medicine 2000, 342:1171-1177. 10.1056/NEJM200004203421604, 10770982.
8. Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist[see comment]. Lancet 2001, 358:1754-1759. 10.1016/S0140-6736(01)06844-1, 11734231.
9. Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. The Journal of clinical endocrinology and metabolism 2002, 87:1692-1699. 10.1210/jc.87.4.1692, 11932303.
10. Fairfield WP, Sesmilo G, Katznelson L, Pulaski K, Freda PU, Stavrou S, Kleinberg D, Klibanski A. Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clinical endocrinology 2002, 57:385-390. 10.1046/j.1365-2265.2002.01624.x, 12201832.
11. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. European Journal of Endocrinology 2006, 154:213-220. 10.1530/eje.1.02079, 16452533.
12. Parkinson C, Burman P, Messig M, Trainer PJ, Parkinson C, Burman P, Messig M, Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. Journal of Clinical Endocrinology & Metabolism 2007, 92:190-195.
13. Paisley AN, O'Callaghan CJ, Lewandowski KC, Parkinson C, Roberts ME, Drake WM, Monson JP, Trainer PJ, Randeva HS, Paisley AN. Reductions of circulating matrix metalloproteinase 2 and vascular endothelial growth factor levels after treatment with pegvisomant in subjects with acromegaly. Journal of Clinical Endocrinology & Metabolism 2006, 91:4635-4640.
14. Parkinson C, Flyvbjerg A, Trainer PJ. High levels of 150-kDa insulin-like growth factor binding protein three ternary complex in patients with acromegaly and the effect of pegvisomant-induced serum IGF-I normalization. Growth hormone & IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society 2004, 14:59-65.
15. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. The Journal of clinical endocrinology and metabolism 2003, 88:5650-5655. 10.1210/jc.2003-030772, 14671148.
16. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology 2006, 154:467-477. 10.1530/eje.1.02112, 16498061.
17. Jehle S, Reyes CM, Sundeen RE, Freda PU, Jehle S, Reyes CM, Sundeen RE, Freda PU. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. Journal of Clinical Endocrinology & Metabolism 2005, 90:1588-1593.
18. Feenstra J, de Herder WW, ten Have SM, Beld AW, Feelders RA, Janssen JA, Lely AJ, Feenstra J, de Herder WW, ten Have SMTH. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly[erratum appears in Lancet. 2005 May;365(9471):1620]. Lancet 2005, 365:1644-1646. 10.1016/S0140-6736(05)63011-5, 15885297.
19. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, Orskov H, Jorgensen JOL, Feldt-Rasmussen U, Frystyk J. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology & Metabolism 2005, 90:5627-5631.
20. Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, D'Errico A, Kourides I, Burman P, Lombardi G. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. Journal of Clinical Endocrinology & Metabolism 2007, 92:476-482.
21. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ, the GPI, Schreiber I, Buchfelder M. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. European Journal of Endocrinology 2007, 156:75-82. 10.1530/eje.1.02312, 17218728.
22. Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ, Parkinson C, Drake WM, Wieringa G, Yates AP. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clinical Endocrinology 2002, 56:303-311. 10.1046/j.1365-2265.2002.01460.x, 11940041.
23. Parkinson C, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton PE, Trainer PJ, Parkinson C, Whatmore AJ, Yates AP. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly. Clinical Endocrinology 2003, 59:168-174. 10.1046/j.1365-2265.2003.01795.x, 12864793.
24. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, Lely AJ, Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. The Journal of clinical endocrinology and metabolism 2005, 90:5684-5691. 10.1210/jc.2005-0331, 16076947.
25. Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ. Pegvisomant interference in GH assays results in underestimation of GH levels. European Journal of Endocrinology 2007, 156:315-319. 10.1530/eje.1.02341, 17322491.
26. Welsh Medicines Partnership Therapeutic Development Assessment Pegvisomant (Somavert®). 2007, Accessed June 2007., http://www.wales.nhs.uk/sites3/Documents/371/Enc%203%20WMP%20Pegvisomant %20report.pdf
27. Bates AS, Van't HW, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993, 86:293-299.
28. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83:2730-2734. 10.1210/jc.83.8.2730, 9709939.
29. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005, 90:4081-4086. 10.1210/jc.2004-1381, 15886256.
30. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab 2004, 89:1613-1617. 10.1210/jc.2003-031584, 15070920.
31. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab 2005, 90:3337-3341. 10.1210/jc.2004-1565, 15755865.
32. Kauppinen-Makelin R, Sane T, Sintonen H, Markkanen H, Valimaki MJ, Loyttyniemi E, Niskanen L, Reunanen A, Stenman UH, Kauppinen-Makelin R. Quality of life in treated patients with acromegaly. Journal of Clinical Endocrinology & Metabolism 2006, 91:3891-3896.
33. Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA, Roelfsema F. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 2004, 89:5369-5376. 10.1210/jc.2004-0669, 15531483.
34. Hua SC, Yan YH, Chang TC, Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. European Journal of Endocrinology 2006, 155:831-837. 10.1530/eje.1.02292, 17132752.
35. Webb SM, Badia X, Surinach NL, . Spanish AcroQol Study Group Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. European Journal of Endocrinology 2006, 155:269-277. 10.1530/eje.1.02214, 16868140.
36. Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM, Christ ER. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin Endocrinol (Oxf) 2005, 63:103-110. 10.1111/j.1365-2265.2005.02307.x, 15963069.
37. British National Formulary 2007, Accessed June 2007., http://www.bnf.org/bnf/
38. NHS reference costs 2005-06, Mental Health Services: Inpatient Data. MHIPA2 adult: acute care 2007, Ref Type: Data File.
39. Moore D, Meads C, Roberts L, Song F. The effectiveness of somatostatin analogues in the treatment of acromegaly. Report 37, West Midlands Health Technology Assessment Collaboration. Department of Public Health & Epidemiology, University of Birmingham 2001, 1-74. Ref Type: Report.
40. Cambridgeshire joint prescribing group decision document Pegvisomant (Somavert, Pfizer) for treatment of acromegaly. 2006, Accessed June 2007., http://www.cambsphn.nhs.uk/documents/CJPG%20Information/Decisions/Pegvis omant%20-%20Decision%20Jan%202006.doc?preventCache=08%2F11%2F2006+16%3A1 4
41. Didoni G, Grottol S, Gasco V, Battistini M, Ferone D, Giusti M, Ragazzoni F, Ruffo P, Ghigo E, Minuto F. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest 2004, 27:1034-1039.
42. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S. Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 2008, 93:3515-3518. 10.1210/jc.2008-0833, 18611977.